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CPs (p < 0. IO). Although the SPs spent less time in REM sleep 
(p<O.O5), further REM sleep parameters, including REM 
latency and REM density, were not altered. 
In conclusion, our findings in drug-naive patients with a first 
episode of a schizophrenic disorder are in favour of an arousal 
linked disturbance at the beginning of the night sleep resulting 
in a delayed sleep onset and a disturbed build-up of SWS. On 
the other hand, we did not observe changes in REM latency 
or REM density in these patients. 
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Based upon the sleep inducing and potential antipsychotic 
effects of benzodiazepines (BZDs), and the relationships 
between negative schizophrenic symptoms and rapid eye move- 
ment sleep (REM) latency and slow wave sleep, we studied 
CSF diazepam-binding inhibitor-like immunoreactivity (DBI- 
LI) and polysomnography in schizophrenic patients. Twenty 
eight drug free male schizophrenic patients (DSMIIIR), 
underwent a three night polysomnography evaluation and a 
lumbar puncture. CSF DBI-LI correlated positively with REM 
latency and stage 4 percent-sleep; while CSF DBI-LI correlated 
negatively with Stage I percent-sleep and REM density. CSF 
DBI-LI did not correlate significantly with duration of sleep 
or sleep latency. Negative symptoms also correlated negatively 
with CSF DBI-LI. CSF DBI-LI did not correlate significantly 
with sleep EEG measures during haloperidol treatment in 17 
of the patients who were evaluated on medication as well. 
While there were positive relationships between CSF DBI-LI 
and sleep measures, the relationships between CSF DBI-LI 
and schizophrenic behavior were negative. The results of this 
first study of the relationship between endogenous DBI and 
sleep in humans suggest a different physiological role for DBI 
than concluded from pharmacological studies. However, the 
absence of similar sleep data in normals precludes us from 
establishing a specific relationship between DBI and sleep in 
schizophrenia. 
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Altered distribution of REM sleep i.e. shortening of REM 
latency, is assumed to be specific for sleep in depression. It 
was demonstrated that stimulation with cholinergic agonists, 
for example RS 86, prior to sleep provokes significantly shorter 
REM latencies in depressives than in controls, supporting the 
theory of a muscarinic supersensitivity in depression. In the 
present study the influence of chohnergic stimulation on REM 
sleep is investigated comparatively in healthy subjects, 
depressed patients and schizophrenic patients. 
We investigated 36 healthy subjects, 39 patients with major 
depression and 39 patients with schizophrenia. All patients 
were drug free for at least 7 days and after an adaptation night 
in the sleep laboratory the patients were given placebo/l .5 mg 
RS 86 in a randomized double-blind order prior to sleep on 
the next two nights. 
RS 86 had the strongest impact on REM latency in depressed 
patients compared to the two other groups. In depression mean 
REM latency was shortened from 47 to 19 min after RS 86 
and in schizophrenic subjects REM latency was shortened from 
67 min to 43 min. Although depressed patients and schizophre- 
nic subjects differed significantly, an unexpected high number 
of extremely shortened REM latencies in schizophrenic patients 
occurred. The results support the hypothesis that muscarinic 
supersensitivity may be implied in the pathophysiology of a 
subgroup of schizophrenic patients. 
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Polysomnographic abnormalities in schizophrenia are poorly 
characterized and the underlying mechanisms and clinical corre- 
lates of such abnormalities are poorly understood. To address 
these issues, we recorded EEG sleep in 20 drug-naive schizo- 
phrenics, 20 drug-free but previously medicated schizophrenics, 
and 20 matched normal controls. Drug-naive and previously 
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medicated patients both had significantly greater impairment 
of sleep continuity and shorter REM latency when compared 
to controls. REM latency was inversely correlated with the 
severity of negative symptoms (r = - 0.52, p < 0.001) but unre- 
lated to depressive symptoms. Considering the role of dopa- 
minergic and cholinergic mechanisms in the regulation of sleep 
measures, these findings are consistent with the model of 
concomitant increases in dopaminergic and cholinergic activity 
in schizophrenia. To further evaluate the cholinergic contribu- 
tion to these sleep findings, we studied the effects of 6 and 
10mg of biperiden (an anticholinergic agent) on REM sleep 
measures in 20 schizophrenic patients (10 patients at each dose) 
and matched normal controls. 6 mg of biperiden produced a 
smaller increase in REM latency in schizophrenic patients; 
10 mg of biperiden produced an equal increase in REM latency 
in both groups. Both doses of biperiden produced a greater 
reduction in REM density in the schizophrenic group. Con- 
sidering that REM latency is predominantly regulated by the 
cholinergic system and REM density by the balance between 
cholinergic and catecholaminergic systems, these findings pro- 
vide further support for the hypothesis of concomitant increases 
in dopaminergic and cholinergic activity in schizophrenia. 
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emerged such as shortened overall sleeping time, fragmented 
sleep, decreased slow wave sleep and REM latency. Antipsy- 
chotic treatment tends to normalize some of these findings. 
However, the lack of consistency across studies of sleep abnor- 
malities in schizophrenia may be explained by methodological 
problems such as lingering after-effects of neuroleptic treatment 
and uncertain clinical state. The authors will present sleep EEG 
data on 25 physically healthy male schizophrenic patients 
(DSMIIIR), ages 25-49, who were studied before and after 
haloperidol withdrawal at varying times drug free. Sleep EEG 
was significantly different in the drug free patients who relapsed 
versus those who did not. Haloperidol withdrawal was associ- 
ated with decreased total sleep, sleep efficiency and mainte- 
nance; decreased REM latency, and overall decreases in stages 
1 through 3 and delta sleep. Relapsers had less total sleep and 
lower sleep efficiency than nonrelapsers in the drug free state. 
Reports examining sleep in schizophrenic patients should 
include information on time drugfree before testing and the 
clinical condition (e.g. relapsed, clinically stable). 
Sleep disturbances have been noted in relapsed and residual 
schizophrenic patients. Only recently some patterns have 
